“We believe the strong patient protections in Part D will help everyone get access to the drugs that are right for them at a lower cost,” Mr Azar said during a recent speech, “but we want your input on how that should work.”
The tenth biosimilar approved in the United States is for the treatment of HIV therapy-related anemia.
In his latest blog, Russ J Spjut, PharmD, owner of Formulary Intel Consulting, discusses how a newly approved HIV treatment could offer hope for low adherence populations due to its low administration burden.
Mylan plans to improve access and increase costs savings within the $20 billion antiretroviral marketplace, by launching 2 of its HIV combination treatments—Symfi Lo and Cimduo—at a significant discount compared with other HIV treatments.
A recent presentation at the European PrEP Summit argues that ignorance surrounding the use of PrEP to prevent HIV is the main barrier to uptake.